MedPath

The New York State Psychiatric Institute

The New York State Psychiatric Institute logo
🇺🇸United States
Ownership
Private
Established
1895-01-01
Employees
251
Market Cap
-
Website
http://www.nyspi.org

Clinical Trials

434

Active:5
Completed:307

Trial Phases

6 Phases

Early Phase 1:4
Phase 1:59
Phase 2:113
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (412 trials with phase data)• Click on a phase to view related trials

Not Applicable
142 (34.5%)
Phase 2
113 (27.4%)
Phase 4
76 (18.4%)
Phase 1
59 (14.3%)
Phase 3
18 (4.4%)
Early Phase 1
4 (1.0%)

Helping Adults With Obsessive-Compulsive Disorder Succeed at Work

Not Applicable
Not yet recruiting
Conditions
Obsessive-Compulsive Disorder (OCD)
First Posted Date
2025-08-15
Last Posted Date
2025-08-15
Lead Sponsor
New York State Psychiatric Institute
Target Recruit Count
40
Registration Number
NCT07124780

A Multimodal Imaging Study of Dopamine in Early Psychosis

Phase 1
Not yet recruiting
Conditions
Clinical High Risk for Psychosis (CHR)
Interventions
First Posted Date
2025-05-18
Last Posted Date
2025-05-18
Lead Sponsor
New York State Psychiatric Institute
Target Recruit Count
115
Registration Number
NCT06977308

Olfactory Training in Mild Cognitive Impairment

Not Applicable
Recruiting
Conditions
Mild Cognitive Impairment
First Posted Date
2025-02-13
Last Posted Date
2025-07-10
Lead Sponsor
Jeffrey Motter
Target Recruit Count
30
Registration Number
NCT06825403
Locations
🇺🇸

New York State Psychiatric Institute, New York, New York, United States

Exercise and Olanzapine-samidorphan

Phase 4
Recruiting
Conditions
Schizophenia Disorder
Schizoaffective Disorder
Bipolar Disorder I or II
Bipolar Disorder NOS
Interventions
Drug: Olanzapine-samidorphan + exercise
First Posted Date
2024-12-18
Last Posted Date
2025-07-11
Lead Sponsor
New York State Psychiatric Institute
Target Recruit Count
30
Registration Number
NCT06740890
Locations
🇺🇸

New York State Psychiatric Institute, New York, New York, United States

Mindfulness-Based Substance Use Prevention (MINDS-UP)

Not Applicable
Not yet recruiting
Conditions
Substance Use
First Posted Date
2024-09-19
Last Posted Date
2025-08-19
Lead Sponsor
New York State Psychiatric Institute
Target Recruit Count
45
Registration Number
NCT06593470
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 87
  • Next

News

Psilocybin Shows Promise in Reducing Symptoms of Body Dysmorphic Disorder

A pilot study indicates that psilocybin significantly reduced symptoms in individuals with body dysmorphic disorder (BDD).

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.